Horizon 2020

SC1 – Health, Demographic change and Wellbeing

BRUNO MOURENZA

Horizon 2020
Punto di Contatto Nazionale
SALUTE
Three Priorities What’s New?

- A **single** programme
- More innovation – “from research to retail”
- Focus on **societal challenges**
- **Simplified** and broader access
Struttura del programma

Excellent Science
- European Research Council
  - Frontier research by the best individual teams
- Future and Emerging Technologies
  - Collaborative research to open new fields of innovation
- Marie Skłodowska Curie actions
  - Opportunities for training and career development
- Research infrastructures (including e-infrastructure)
  - Ensuring access to world-class facilities

Industrial Technologies
- Leadership in enabling and industrial technologies
  - ICT, nanotechnologies, materials, biotechnology, manufacturing, space
- Access to risk finance
  - Leveraging private finance and venture capital for research and innovation
- Innovation in SMEs
  - Fostering all forms of innovation in all types of SMEs

Societal Challenges
- Health, demographic change and wellbeing
- Food security, sustainable agriculture, marine and maritime research & the bioeconomy
- Secure, clean and efficient energy
- Smart, green and integrated transport
- Climate action, resource efficiency and raw materials
- Inclusive, innovative and reflective societies
- Security society

European Institute of Innovation and Technology (EIT)
Spreading Excellence and Widening Participation
Science with and for society
Joint Research Center (JRC)
Ripartizione finanziaria globale

- Excellent Science: 32%
- Societal Challenges: 39%
- Industrial Leadership: 22%
- EIT Science: 3%
- Widening: 1%
- JRC: 2%

@APRE 2013
Excellent Science

- European Research Council
- Future and Emerging Technologies
- Mario Sklodowska Curie Actions
- European Research Infrastructures (including eInfrastructures)

Societal challenges

- 25%
- 10%
- 6%
- 5%
- 10%
- 21%
- 20%
- 13%

Industrial Leadership

- 80% Leadership in enabling and Industrial technologies
- 16% Access to risk finance
- 4% Innovation in SMEs

- Health, demographic change and wellbeing
- Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the bioeconomy:
  - Secure, clean and efficient energy
  - Smart, green and integrated transport
  - Climate action, environment, resource efficiency and raw materials
  - Inclusive, innovative and reflective Societies
  - Secure Societies
<table>
<thead>
<tr>
<th>Descrizione</th>
<th>Percentuale</th>
<th>Millione € (27.06.13)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Excellent Science, of which:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. ERC</td>
<td>17,60%</td>
<td>11.577</td>
</tr>
<tr>
<td>2. FET</td>
<td>3,50%</td>
<td>2.384</td>
</tr>
<tr>
<td>3. MS Curie Actions</td>
<td>8,00%</td>
<td>5.448</td>
</tr>
<tr>
<td>4. Research Infrastructures</td>
<td>3,23%</td>
<td>2.200</td>
</tr>
<tr>
<td>II. Industrial Leadership, of which:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leadership in Enabling and Industrial Technologies</td>
<td>17,60%</td>
<td>11.986</td>
</tr>
<tr>
<td>Access to Risk Finance</td>
<td>3,69%</td>
<td>2.513</td>
</tr>
<tr>
<td>Innovation in SME's</td>
<td>0,80%</td>
<td>544,81</td>
</tr>
<tr>
<td>II.I Societal Challenges, of which:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health, demographic change and well being</td>
<td>9,70%</td>
<td>7.472</td>
</tr>
<tr>
<td>Food security, sustainable agriculture, marine and maritime research &amp; the bio economy</td>
<td>5,00%</td>
<td>3.405</td>
</tr>
<tr>
<td>Secure, clean and efficient energy</td>
<td>7,70%</td>
<td>5.244</td>
</tr>
<tr>
<td>Smart, green and integrated transport</td>
<td>8,23%</td>
<td>5.605</td>
</tr>
<tr>
<td>Climate action, resource efficiency and raw materials</td>
<td>4,00%</td>
<td>2.724</td>
</tr>
<tr>
<td>Europe in a changing world – Inclusive, innovative and reflective society</td>
<td>1,70%</td>
<td>1.158</td>
</tr>
<tr>
<td>Secure societies – Protecting freedom and security of Europe and its citizens</td>
<td>2,20%</td>
<td>1.498</td>
</tr>
<tr>
<td>Spreading Excellence and Widening Participation</td>
<td>1,06%</td>
<td>722</td>
</tr>
<tr>
<td>Science with and for society</td>
<td>0,60%</td>
<td>409</td>
</tr>
<tr>
<td>European Institute of Innovation and Technology - EIT</td>
<td>3,52%</td>
<td>2.397</td>
</tr>
<tr>
<td>JRC Non-nuclear</td>
<td>2,47%</td>
<td>1.682</td>
</tr>
<tr>
<td>EURATOM</td>
<td></td>
<td>2.098</td>
</tr>
<tr>
<td>Total</td>
<td>100,00%</td>
<td>70.200</td>
</tr>
</tbody>
</table>

Il calcolo del budget per programma è stato elaborato da APRE sulla base delle percentuali stabilite durante il Consiglio.
1° PILLAR

EXCELLENT SCIENCE
Excellent Science

- European Research Council
  - Frontier research by the best individual teams

- Future and Emerging Technologies
  - Collaborative research to open new fields of innovation

- Marie Skłodowska Curie actions
  - Opportunities for training and career development

- Research infrastructures
  - (including e-infrastructure)
  - Ensuring access to world-class facilities

Industrial Technologies

- Leadership in enabling and industrial technologies
  - ICT, nanotechnologies, materials, biotechnology, manufacturing, space

- Access to risk finance
  - Leveraging private finance and venture capital for research and innovation

- Innovation in SMEs
  - Fostering all forms of innovation in all types of SMEs

Societal Challenges

- Health, demographic change and wellbeing

- Food security, sustainable agriculture, marine and maritime research & the bioeconomy

- Secure, clean and efficient energy

- Smart, green and integrated transport

- Climate action, resource efficiency and raw materials

- Inclusive, innovative and reflective societies

- Security society
Rationale:

- La Scienza di Eccellenza è alla base delle tecnologie di domani, del lavoro e del benessere
- L’Europa ha bisogno di formare, attrarre e trattenere i ricercatori talentuosi
- I ricercatori necessitano l’accesso alle migliori infrastrutture
Per sostenere le migliori idee e sviluppare competenze, per fare dell’Europa un polo di attrazione per i migliori ricercatori mondiali

**European Research Council:** progetti di ricerca di frontiera

**Future and Emerging Technologies:** ricerca nelle aree più promettenti nel campo delle tecnologie di domani; *(Science)*

Azioni **Marie Skłodowska-Curie** per attrarre e sostenere ricercatori e la loro mobilità;

**Infrastrutture di Ricerca** adeguate, meno care e diffuse in Europa.
2° PILLAR

INDUSTRIAL LEADERSHIP
### Struttura del programma

#### Excellent Science
- European Research Council
  - Frontier research by the best individual teams

- Future and Emerging Technologies
  - Collaborative research to open new fields of innovation

- Marie Skłodowska Curie actions
  - Opportunities for training and career development

- Research infrastructures (including e-infrastructure)
  - Ensuring access to world-class facilities

#### Industrial Technologies
- **Leadership in enabling and industrial technologies**
  - ICT, nanotechnologies, materials, biotechnology, manufacturing, space

- **Access to risk finance**
  - Leveraging private finance and venture capital for research and innovation

- **Innovation in SMEs**
  - Fostering all forms of innovation in all types of SMEs

#### Societal Challenges
- Health, demographic change and wellbeing
- Food security, sustainable agriculture, marine and maritime research & the bioeconomy
- Secure, clean and efficient energy
- Smart, green and integrated transport
- Climate action, resource efficiency and raw materials
- Inclusive, innovative and reflective societies
- Security society

---

**European Institute of Innovation and Technology (EIT)**

Spreading Excellence and Widening Participation

Science with and for society

Joint Research Center (JRC)
Industrial Leadership/2

Per incoraggiare investimenti in R&I in Europa, promovendo alcune priorità per ogni forma di business

- **Leadership in enabling and industrial technologies** - soprattutto Key enabling technologies (Information and Communication Technologies (ICT), Nanotechnologies, Advanced materials, Biotechnology, Advanced Manufacturing and Processing) & Space;

- **Access to finance** per aziende innovative, strumenti finanziari in partenariato con l’European Investment Bank; Debt instrument & Equity instrument

- **Innovation in SME**
  Support to innovative SMEs
Industrial Leadership/2

Rationale:

- Gli investimenti strategici nelle tecnologie-chiave (es. tecnologie industriali avanzate, microelettronica) rafforzano l’innovazione nei settori già maturi e in quelli emergenti

- L’Europa ha bisogno di attrarre ulteriori investimenti privati in ricerca e innovazione

- L’Europa necessita di un numero maggiore di PMI innovative capaci di stimolare la crescita e creare posti di lavoro
SOCIETAL CHALLENGES

3° PILLAR
### Excellent Science
- European Research Council
  - Frontier research by the best individual teams
- Future and Emerging Technologies
  - Collaborative research to open new fields of innovation
- Marie Skłodowska Curie actions
  - Opportunities for training and career development
- Research infrastructures (including e-infrastructure)
  - Ensuring access to world-class facilities

### Industrial Technologies
- Leadership in enabling and industrial technologies
  - ICT, nanotechnologies, materials, biotechnology, manufacturing, space
- Access to risk finance
  - Leveraging private finance and venture capital for research and innovation
- Innovation in SMEs
  - Fostering all forms of innovation in all types of SMEs

### Societal Challenges
- Health, demographic change and wellbeing
- Food security, sustainable agriculture, marine and maritime research & the bioeconomy
- Secure, clean and efficient energy
- Smart, green and integrated transport
- Climate action, resource efficiency and raw materials
- Inclusive, innovative and reflective societies
- Security society
Rationale:

Le preoccupazioni condivise dai cittadini e dalla società e gli obiettivi politici dell’agenda europea (clima, ambiente, energia, trasporti, ecc) non possono essere affrontate e realizzati senza innovazione.

Le soluzioni brillanti derivano da collaborazioni multidisciplinari, dove giocano un ruolo di primo piano anche le scienze sociali e umane.

Le soluzioni promettenti devono essere testate, dimostrate e progressivamente sviluppate.
1. HEALTH, DEMOGRAPHIC CHANGE AND WELLBEING
### H2020 Work Programmes: Multi-annual Programming

<table>
<thead>
<tr>
<th>Year</th>
<th>Strategic Programme</th>
<th>Work Programme 1</th>
<th>Work Programme 2</th>
<th>Work Programme 3</th>
<th>Work Programme 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2019</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Strategic programmes:** short documents outlining priorities over 3 years, updated every two years.
- **Work Programmes:** mirror the strategic programme and are updated over the same 2-year cycle.
- **Smaller and continuous updates:** to respond to unexpected developments.

**Calls published on basis of WP:**
- Ad hoc financing decision
- Calls published on basis of WP
- Ad hoc financing decision
- Calls published on basis of WP
- Ad hoc financing decision
- Calls published on basis of WP
First work programs will be developed around a limited set of focus areas

- **Personalizing health and care**
- **Sustainable food security**
- **Blue growth: unlocking the potential of the oceans**
- **Smart cities and communities**
- **Competitive low-carbon energy**
- **Mobility for growth**
- **Innovation in Public Sector & social innovation** (pilot calls, other programmes “ISA”..etc.)
- **Waste: a resource to recycle, reuse and recover raw materials**
- **New ideas, strategies and governance structures for Europe**
- **Disaster-resilience: safeguarding and securing society, including adapting to climate change**
- **Digital security**
- **Energy Efficiency**

A strong initial emphasis will be to support Member States and regions in the effective implementation of the new research and innovation programmes under the Structural Funds...
Personalised medicine – towards a definition

"Personalised medicine refers to a medical model using molecular profiling for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention"
The Horizon 2020 societal challenge of ‘Health, Demographic change and Wellbeing’ (SC1) for the years 2014 and 2015

Includes 36 topics in the ‘personalising health and care’ focus area call, and 15 topics in the ‘co-ordination activities’ call.

The total budget available is approximately EUR 1.20bn.

Topics in the call are divided into 7 areas.

Societal challenge 1 is also implemented by the Innovative Medicines Initiative (IMI), the European and Developing Countries Clinical Trials Partnership (EDCTP), the Active and Assisted Living programme (AAL) and the European Innovation Partnership on Active and Healthy Ageing (EIP-AHA).

Many topics will be evaluated in two stages. Exceptions to the two stage approach include a number of ‘close to market’ type topics, including those which make use of the SME instrument.
Where are we now in health?

On content?

Call for *Personalizing Health and Care 2014-2015*

1.1. Understanding health, ageing and disease

1.2. Effective health promotion, disease prevention, preparedness and screening

1.3. Improving diagnosis

1.4. Innovative treatments and technologies

1.5. Advancing active and healthy ageing

1.6. Integrated, sustainable, citizen-centred care

1.7. Improving health information, data exploitation and providing an evidence base for health policies and regulation

IMI, AAL, EDCTP cutting across
Strategic Initiatives

Innovative Medicines Initiative 2
www.imi.europa.eu

European Innovation Partnership on Active and Healthy Ageing
https://webgate.ec.europa.eu/eipaha

Active and Assisted Living 2
www.aal-europe.eu

European & Developing Countries Clinical Trials Partnership (EDCTP2)
www.edctp.org
“Diagnostic tools for poverty-related diseases”
Deadline 2nd March 2015
PRIMI RISULTATI
Health - Horizon 2020
### Bando 2014 Health, Demographic change and Wellbeing

<table>
<thead>
<tr>
<th>No. topics</th>
<th>Budget Mill. EUR</th>
<th>Proposte presentate</th>
<th>Proposte finanziate</th>
<th>Tasso di successo</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>488,2</td>
<td>1056</td>
<td>95</td>
<td>9%</td>
</tr>
</tbody>
</table>

#### Partecipazione

<table>
<thead>
<tr>
<th>No. Partecipanti italiani in proposte presentate</th>
<th>No. Partecipanti italiani finanziati</th>
<th>Tasso di successo partecipanti Italiani</th>
</tr>
</thead>
<tbody>
<tr>
<td>1125</td>
<td>101</td>
<td>8,9%</td>
</tr>
</tbody>
</table>

Contributo finanziario per l’Italia (rientro)

<table>
<thead>
<tr>
<th></th>
<th>37.855.706 €</th>
</tr>
</thead>
</table>

#### Coordinamento

<table>
<thead>
<tr>
<th>No. Proposte presentate a coordinamento italiano</th>
<th>No. Coordinamenti italiani finanziati</th>
<th>Tasso di successo coordinatori Italiani</th>
</tr>
</thead>
<tbody>
<tr>
<td>136 (12,8% del totale EU)</td>
<td>9 (9,4% del totale EU)</td>
<td>6,6%</td>
</tr>
</tbody>
</table>

Single RTD 5.502.933 €
Single CONNECT 12.672.135 €
Two-Stages: 19.680.638 €
Coordinamento italiano totale

Proposte a coordinamento presentate
Proposte a coordinamento finanziate
Tasso di successo
Partecipazione italiana totale
## ERA-Nets finanziate in Horizon 2020

<table>
<thead>
<tr>
<th>Project</th>
<th>Description</th>
<th>Partner</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>E-Rare-3</strong></td>
<td>ERA-NET rare disease research implementing IRDiRC objectives</td>
<td>AGENCE NATIONALE DE LA RECHERCHE</td>
<td>FR</td>
</tr>
<tr>
<td><strong>ERACoSysMed</strong></td>
<td>ERACoSysMed - Collaboration on systems medicine funding to promote the implementation of systems biology approaches in clinical research and medical practice</td>
<td>FORSCHUNGSZENTRUM JUELICH GMBH</td>
<td>DE</td>
</tr>
<tr>
<td><strong>JPco-fuND</strong></td>
<td>ERA-NET for establishing synergies between the Joint Programming on Neurodegenerative Diseases Research and Horizon 2020</td>
<td>INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)</td>
<td>FR</td>
</tr>
<tr>
<td><strong>TRANS Can-2</strong></td>
<td>ERA-NET: Aligning national/regional translational cancer research programmes and activities</td>
<td>MINISTERO DELLA SALUTE</td>
<td>IT</td>
</tr>
</tbody>
</table>
Single Stage (24 Febbraio 2015) – DG RTD

✓ **PHC-09-2015**: Vaccine development for poverty-related and neglected infectious diseases: HIV/AIDS

✓ **PHC-15-2015**: Clinical research on regenerative medicine

✓ **PHC-33-2015**: New approaches to improve predictive human safety testing

Single Stage (21 Aprile 2015) – DG CONNECT

✓ **PHC-21-2015**: Advancing active and healthy ageing with ICT: Early risk detection and intervention

✓ **PHC-25-2015**: Advanced ICT systems and services for integrated care

✓ **PHC-27-2015**: Self-management of health and disease and patient empowerment supported by ICT

✓ **PHC-28-2015**: Self management of health and disease and decision support systems based on predictive computer modelling used by the patient him or herself

✓ **PHC-29-2015**: Public procurement of innovative eHealth services

✓ **PHC-30-2015**: Digital representation of health data to improve disease diagnosis and treatment
What’s next?  WP 2016-2017 (under discussion)

1.1. Understanding health, well-being and disease
1.1.1. Understanding the determinants of health, improving health promotion and disease prevention
1.1.2. Understanding disease
1.1.3. Improving surveillance and preparedness

1.2. Preventing disease
1.2.1. Developing effective prevention and screening programmes and improving the assessment of diseases susceptibility
1.2.2. Improving diagnosis and prognosis
1.2.3. Developing better preventive and therapeutic vaccines

1.3. Treating and managing disease
1.3.1. Treating disease, including developing regenerative medicine
1.3.2. Transferring knowledge to clinical practice and scalable innovation actions

1.4. Active ageing and self-management of health
1.4.1. Active ageing and independent and assisted living
1.4.2. Individual awareness and empowerment for self-management of health

1.5. Methods and data
1.5.1. Improving health information and better use of health data
1.5.2. Improving scientific tools and methods to support policy making and regulatory needs
1.5.3. Using in-silico medicine for improving disease management and prediction

1.6. Health care provision and integrated care
1.6.1. Promoting integrated care
1.6.2. Optimising the efficiency and effectiveness of health care provision and reducing inequalities by evidence-based decision making and dissemination of best practice, and innovative technologies and approaches
ALTRE OPPORTUNITÀ DI FINANZIAMENTO NEL SETTORE DELLA SALUTE
Innovative Medicines Initiative:
Joining forces in the healthcare sector

The European Union and the pharmaceutical industry have joined forces to make drug R&D processes in Europe more innovative and efficient, enhance Europe’s competitiveness & address key societal challenges by forming the biggest PPP in Life Science.
• IMI è una partnership pubblico-privata che unisce la Commissione Europea e la Federazione delle Industrie Farmaceutiche Europee (EFPIA)

• IMI è stata creata allo scopo di finanziare la ricerca collaborativa pre-competitiva nel campo dell’efficienza e sicurezza dei farmaci indirizzati ad un ristretto nucleo di patologie
R&D bottlenecks da superare:

1. **Sicurezza**: rendere i farmaci più sicuri

2. **Efficienza**: rendere i farmaci più efficaci, concentrando l’attività di ricerca su 5 aree di maggiore interesse: cancro, malattie cerebrali, malattie infiammatorie, diabete e malattie infettive

3. **Knowledge Management**: L’impiego di nuove tecnologie consente di creare e gestire dati in modo più efficace e rendere più facile il calcolo dei rischi e delle opportunità connessi all’attività di ricerca

4. **Education e Training**: per colmare il gap tra Europa e i suoi diretti competitor (USA e Giappone)
Chi può partecipare?

La partecipazione ai progetti è aperta a tutti i soggetti giuridici e organizzazioni internazionali che soddisfino i criteri di partecipazione minimi necessari, quali:

- **Essere personalità giuridiche autonome** stabilite all'interno di uno Stato Membro o di un Paese Associato al VII Programma Quadro.
- **Le attività di ricerca devono essere sviluppate all'interno di uno Stato Membro o di un Paese Associato** a Horizon 2020.
- **La partnership di ricerca deve essere composta da almeno 2 enti appartenenti a EFPIA e da 2 che non fanno parte di EFPIA** (PMI, istituzioni accademiche, ospedali, associazioni di pazienti, altri enti no-profit).
- **Gli enti che intendono partecipare devono avere capacità di ricerca scientifica**.

How to apply: a 2-stage process

**Stage 1**

- **Submission of Expressions of interest**
  - by Applicant Consortia (academics, SMEs, patients...)
  - 1st peer review: assessment + ranking by independent experts + EFPIA topics coordinators
  - Approval of the 1st ranked consortia by IMI Governing Board
  - Invitation to submit Full Project Proposal to first ranked Applicant Consortium + EFPIA Consortium

**Stage 2**

- **Evaluation of feasibility and scientific excellence**
  - Submission of Full Project Proposal best ranked Applicant Consortium + EFPIA Consortium = Full Project Consortium
  - Evaluation through 2nd peer review, including ethical evaluation by independent experts
  - Approval of the projects by IMI Governing Board

~ 5 months

~ 4 months
Future Topics

Research and Innovation Actions (RIA)  IMI-2 Call 3 Deadline Stage-I: 24 March 2015

- Remote assessment for disease and relapse (RADAR), topic 1: central nervous system (CNS)
- Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification
- Linking clinical neuropsychiatry and quantitative neurobiology
- The consistency approach to quality control in vaccine manufacture
- Pertussis vaccination research
- Knowledge Repository to enable patient focused medicine development

Coordination and Support Action (CSA)  IMI-2 Call 4 Deadline Stage-I: 11 February 2015

- Enabling platform on medicines adaptive pathway to patients

http://www.imi.europa.eu/content/future-topics
Active & Healthy Ageing
A European Innovation Partnership
EIP (European Innovation Partnership on Active and Healthy Ageing) è una iniziativa che promuove una serie di progetti per migliorare la qualità della vita dei Senior e per monitorare i servizi ad essi destinati.

Questo progetto pilota mira ad aumentare di due anni la vita media in buona salute degli europei entro il 2020. A tal fine si propone di:

- Migliorare la salute e la qualità della vita (in particolare delle persone anziane).
- Garantire la sostenibilità ed efficienza dei sistemi sanitari ed assistenziali nel lungo periodo.
- Migliorare la competitività del comparto europeo con attività economiche e un'espansione ai nuovi mercati.
- Consentire alla popolazione di invecchiare restando attivi e in buona salute è una sfida condivisa da tutti i paesi europei.
I settori d'intervento prioritari sono stati individuati nel piano strategico di attuazione e nel piano operativo, adottati nel 2011 dal gruppo direttivo incaricato dell'avvio e dell'attuazione della partnership.

Per realizzare il piano tutti i soggetti interessati hanno iniziato a collaborare nell'ambito di gruppi d'azione.

✓ Action Group A1: Prescription and adherence action at regional level.
✓ Action Group B3: Integrated care for chronic diseases, including remote monitoring at regional level.
✓ Action Group C2: Interoperable independent living solutions.
✓ Action Group D4: Age friendly buildings, cities and environments.

Stakeholders wishing to get involved in the advancing of Specific Actions have formed Action Groups through the "Invitation for Commitment" application process. In each Action Group, stakeholders commit to running a number of activities, contributing towards the headline target, starting with the creation and implementation of an Action Plan.
E' attivo online anche un "**Marketplace per idee innovative**", che rientra in EIP.

E' uno spazio interattivo per scambiare opinioni, trovare partners o iniziative al fine di mettere in pratica delle idee innovative:

https://webgate.ec.europa.eu/eipaha/

**Per ulteriori Informazioni:**

http://ec.europa.eu/research/innovation-union/index_en.cfm?section=active-healthy-ageing
La strategia del JPND rappresenta una visione per coordinare la ricerca nell'ambito delle malattie neurodegenerative, in particolare l'Alzheimer. Si affronta l'intero spettro di attività di ricerca che è necessario per affrontare il peso crescente di queste patologie per il prossimo decennio e oltre.

L'obiettivo del Programma Congiunto (JPND)* è quello di migliorare rapidamente la nostra comprensione delle cause di questo tipo di malattie. Oltre a fornire ai medici gli strumenti per diagnosticare e trattare queste malattie sin dalla fase precoce, il JPND dovrebbe anche portare ad un migliore sistema di assistenza sanitaria e sociale sia per i pazienti che per chi si prende cura di loro.

*The JPND diseases are:

Alzheimer’s disease (AD) and other dementias, Parkinson’s disease (PD) and PD related disorders, Prion disease, Motor neurone diseases (MND), Huntington’s Disease (HD), Spinocerebellar ataxia (SCA), Spinal muscular atrophy (SMA)
Implementation Plan

A first-phase JPND Implementation Plan has been agreed for the period of 2012-2014. The plan has these major action areas:

Annual Calls for Proposals
Action Groups to determine research needs and opportunities
Action Groups to promote engagement, commitment and partnerships
Annual Calls for Proposals

JPND intends to launch Calls for proposals each year to address high priority areas in neurodegenerative disease research. Over the period of 2012-2014, it is anticipated that JPND will launch calls to address each of the following priority areas:

- **Next Call** Deadline: 10th March 2015 (2-stages evaluation)


  - **Topic 1:** Genetic, epigenetic and environmental risk and protective factors of neurodegenerative diseases
  - **Topic 2:** Longitudinal cohort approaches in neurodegenerative diseases
  - **Topic 3:** Advanced animal or cell experimental models of neurodegenerative diseases

NEW Partnering Tool

Per ulteriori informazioni:

**Adriana Maggi**, Ph.D.
Member of the JPND Management Board
Director Center of Excellence on Neurodegenerative Diseases University of Milan
adriana.maggi@unimi.it

JPND FAQ’s: [http://www.neurodegenerationresearch.eu/initiatives/annual-calls-for-proposals/faq/](http://www.neurodegenerationresearch.eu/initiatives/annual-calls-for-proposals/faq/)

**JPND website**

secretariat@jpnd.eu
SERVIZI A SUPPORTO DEL NETWORKING

E RICERCA DI NUOVI PARTNER
Welcome to HealthCompetence

This website includes all projects related to life science and health supported by the European Commission since 2004. It gives visibility to organisations and scientists involved in these projects and, together with interactive search devices, facilitates the identification of potential collaboration partners and the set up of partnerships between academia and industry in health research.

HealthCompetence will also progressively give access to the research results in terms of technology offers, patents and publications.

Simple Search

Project Search
find Projects by research field, country and more

Person Search
find Organisations and Persons

Generate your report
use a set of reports to answer your questions on research funded by the European Commission

Upcoming Events

www.HealthCompetence.eu
An open, pan-European infrastructure for information on research projects & results within Health Science

Help & Support:
support@avedas.com

Online Survey:
Please take part in our survey
HealthCompetence Online Survey.
http://www.fitforhealth.eu/
Create a new Profile

Fields with * are required.

I. Organisation Details

Research Activities *

II. FP European Projects

Former participation in an FP European Project ?

- No
- Yes

Project Title / Acronym

Activities performed

III. Expertise / Commitments Offered

Keywords specifying the expertise *

Description of the expertise *

Commitment offered *

- technology development
- dissemination
- demonstration
- research
- training

If other commitment offered, please specify here

Call Topics

Select Topics


IV. Expectations

Term Commitment *

- Short (<1 year)
- Medium (1 to 3 years)
- Long (> 3 years)

Expected results for your organisation *

V. Personal Information

Would you agree that your identity is displayed with the profile? Should you prefer confidential treatment of your identity, only the expert in service of your profile will be displayed...

Display my identity with this profile:

- No
- Yes

Create
Create a new Project

Fields with * are required.

I. Project Details

Project Title *

Acronym

Project Types *
- Research and Innovation Action (R&I) - 100% funding scheme
- SME Instrument
- Pre-Commercial Procurement (PCP)
- Inducement Prize
- ERA-NET Co-Fund (only for member states)
- Innovation Action (IA) - 70% funding scheme
- Fast-Track to Innovation (FTI2)
- Public Procurement of Innovative Solutions (PPIS)
- Coordination and Support Action (CSA)
- If other project type, please specify here

Status *
- Planned for submission
- Running project

II. Profile of SME or other Organization Sought

Roles *
- Technology development
- Dissemination
- Demonstration
- Research
- Training
- If other role, please specify here

Country / Region *

III. Personal Information

Would you agree that your identity is displayed with the profile? Should you prefer confidential treatment of your identity, only the expert in service of your profile will be displayed...

Publish User Info *
- No
- Yes

Create
GRAZIE PER L’ATTENZIONE!

APRE
Agenzia per la Promozione della Ricerca Europea
via Cavour, 71
00184 - Roma
www.apre.it
Tel. (+39) 06-48939993
Fax. (+39) 06-48902550

Bruno Mourenza
Health NCP
mourenza@apre.it